Evaluation of thrombotic children with malignancy

Annals of Hematology

Volumn 84, Issue 6, 2005, Pages 395-399

  Ünal, Selma ^a   Varan, Ali ^a   Yalçın, Bilgehan ^a   Büyükpamukçu, Münevver ^a   Gürgey, Aytemiz ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Catheter; Children; Congenital risk factors; L Asparaginase; Malignancy; Thrombosis

Indexed keywords

ANTITHROMBIN III; ASPARAGINASE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; LIPOPROTEIN A; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTITHROMBIN III DEFICIENCY; ARTICLE; CENTRAL VENOUS CATHETERIZATION; CHILD; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENETIC RISK; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; INFANT; INFECTION; INHERITANCE; INTRACARDIAC THROMBOSIS; KIDNEY VEIN THROMBOSIS; MAINTENANCE THERAPY; MALE; MALIGNANT NEOPLASTIC DISEASE; MESENTERIC VEIN THROMBOSIS; NONHODGKIN LYMPHOMA; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOGENESIS; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK ASSESSMENT; RISK FACTOR; THROMBOGENESIS; THROMBOSIS;

EID: 20444507623     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1004-x     Document Type: Article

References (26)

1. Sutherland DE, Weitz IC, Liebman HA (2003) Thromboembolic complications of cancer epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 72:43-52 10.1002/ajh.10263
2. Lee AY, Levine MN (2003) Venous thromboembolism and cancer: Risks and outcomes. Circulation 17:117-121
3. Rodger LB (2003) Thrombosis and thrombophilia: Diagnosis and management. Hematol Oncol Clin North Am 17:9-37
4. Falanga A, Rickles FR (1999) Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 25:173-181
5. Gouin I, Samama M (1999) Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost 25:167-172
6. Bick RL (2003) Cancer-associated thrombosis. N Engl J Med 349:109-111
7. Bell RW (1996) The fibrinolytic system in neoplasia. Semin Thromb Hemost 22:459-478
8. Guarini A, Mussoni A, Gugliatta L, Chetti L, Niewiarowski T, Catani L, Macchi S, Donati MB, Tura S (1987) Depressed fibrinolysis in patients with acute leukemia. Br J Haematol 66:327-330
9. Goldschmidt B, Koos R (1984) Metabolism of fibrinogen in children with acute lymphoblastic leukemia. Eur J Pediatr 143 140-144
10. Semeraro N, Montemurro P, Giardona P, Schettini F, Santoro N, Mattia D, Giordano D, Ronese M, Colucci M (1990) Unbalanced coagulation fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukemia. Thromb Haemost 64:38-40
11. Nowak-Göttl U, Heineche A, Von Kries R, Nürnberger W, Münchow N, Junker R (2001) Thrombotic events revisited in children with acute lymphoblastic leukemia: Impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 103:165-172
12. Wilimas JA, Hudson M, Rao B, Luo X, Lott L, Kaste SC (1998) Late vascular occlusion of central lines in pediatric malignancies. Pediatrics 101:1-5
13. Bona DR (1999) Thrombotic complication of central venous catheters in cancer patients. Semin Thromb Hemost 25:147-155
14. Ehrenforth S, Junker R, Koch HG, Kreuz W, Münchow N, Scharrer I, Nowak-Göttl U (1999) Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Eur J Pediatr 158 97-104
15. Nowak-Göttl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack, Schwabe D, Ehrenforth S (1999) Prospective evaluation of the thrombotic risk in children with acute leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 93:1595-1599
16. Nowak-Göttl U, Dübbers A, Kececioglu D, Koch GH, Kotthoff S, Runde J, Vielhaber H (1997) Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: A prospective study. J Pediatr 131:608-612
17. Wermes C, Prondzinski D, Lichtinghagen R, Barthels M, Welte K, Sykora KW (1999) Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 158:143-146
18. Knofler R, Siegert E, Lauterbach I, Taut-Sack H, Siegert G, Gehrisch S, Müller D, Rupprecht E, Kabus M (1999) Clinical importance of prothrombotic risk factors in pediatric patients with malignancy - impact of central venous lines. Eur J Pediatr 158 [Suppl 3]:S147-S150
19. Sifontes MT, Nuss R, Hunger SP, Williams J, Jacobson LS, Manco-Johnson MJ (1997) The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 96:484-498
20. Gurgey A, Buyukpamukcu M, Baykurt C, Yalcin B, Gogus S (1997) Portal vein thrombosis in association with factor V Leiden mutation in a patient with hepatocellular carcinoma. Med Pediatr Oncol 56:189-190
21. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H et al (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67 10.1038/369064a0
22. Poort SR, Rosendaal FR, Reistma PH, Bertina RM (1996) A common genetic variation in the 3-prime-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698-3703 1:CAS:528:DyaK28XntVahsLg%3D
23. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850 10.1056/NEJM200012213432504
24. Gurgey A, Mesci L (1997) The prevalence of factor V Leiden (1691 G-A) mutation in Turkey. Turk J Pediatr 39:313-315
25. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D et al (1994) Venous thromboembolic complications (VTE) in children: First analyses of the Canadian registry of VTE. Blood 83:1251-1257 1:STN:280:ByuC283mt1c%3D
26. Nowak-Göttl U, Junker R, Hartmaier H, Koch HG, Münchow N, Assmann G, Von Eckardstein A (1999) Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 100:743-748